Clinical Trial Update: Metabolic and Cardiovascular Effects of Dipeptidyl Peptidase-4 (DPP-4) or Sodium-glucose Co-transporter Type 2 (SGLT2) Inhibitors [Phase 4]

View source ↗

Summary

Clinical trial update evaluating the metabolic and cardiovascular effects of DPP-4 inhibitors and SGLT2 inhibitors in individuals with diabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• DPP-4 inhibitors
• SGLT2 inhibitors (SGLT2 inhibitor)

Snippet

Sponsor: Kurume University | Conditions: Effects of the DPP-4 Inhibitors or SGLT2 Inhibitors on the Protective Actions for Diabetic Complications | Phase 4 | Status: UNKNOWN